Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 6, 2016, Pages 581-589

  Skov, J ^a,b   Pedersen, M ^a,c   Holst, J J ^d   Madsen, B ^a   Goetze, J P ^d   Rittig, S ^a   Jonassen, T ^d   Frokiaer J ^a,c   Dejgaard, A ^b   Christiansen, J S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

atrial natriuretic peptide; catecholamines; glomerular filtration rate; glucagon like peptide 1; liraglutide; renal; renin angiotensin system; type 2 diabetes

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; ATRIAL NATRIURETIC FACTOR; CATECHOLAMINE; HEMOGLOBIN A1C; LIRAGLUTIDE; LITHIUM; METFORMIN; RENIN; PLACEBO;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESTIMATED GLOMERULAR FILTRATION RATE; HEART RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TISSUE OXYGENATION; TISSUE PERFUSION; TREATMENT DURATION; UNIVERSITY HOSPITAL; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY; KIDNEY CIRCULATION; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ADULT; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PLACEBOS; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84995609063     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12651     Document Type: Article

References (40)

1. Collins AJ, Foley RN, Chavers B et al. US renal data system 2013 annual data report. Am J Kidney Dis 2014; 63: A7.
2. Skov J. Effects of GLP-1 in the Kidney. Rev Endocr Metab Disord 2014; 15: 197–207.
3. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
4. Skov J, Dejgaard A, Frokiaer J et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98: E664–E671.
5. Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055–3061.
6. Muskiet MH, Tonneijck L, Smits MM et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab 2016; 18: 178–185.
7. Asmar A, Simonsen L, Asmar M et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 2015; 308: E641–E649.
8. Pyke C, Heller RS, Kirk RK et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280–1290.
9. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736–743.
10. Jensen EP, Poulsen SS, Kissow H et al. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Renal Physiol 2015; 308: F867–F877.
11. Kim M, Platt MJ, Shibasaki T et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567–575.
12. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect 2014; 3: 11–16.
13. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132–139.
14. Ishibashi Y, Matsui T, Ojima A et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res 2012; 84: 395–398.
15. Hirata K, Kume S, S-i A et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44–49.
16. Mima A, Hiraoka-Yamomoto J, Li Q et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967–2979.
17. Fujita H, Morii T, Fujishima H et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85: 579–589.
18. Hendarto H, Inoguchi T, Maeda Y et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61: 1422–1434.
19. Imamura S, Hirai K, Hirai A. The glucagon-like Peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 2013; 231: 57–61.
20. Davies MJ, Bain SC, Atkin SL et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 2016; 39: 222–230.
21. Elbrønd B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398–1404.
22. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984; 37: 217–223.
23. Khatir DS, Pedersen M, Jespersen B, Buus NH. Reproducibility of MRI renal artery blood flow and BOLD measurements in patients with chronic kidney disease and healthy controls. J Magn Reson Imaging 2014; 40: 1091–1098.
24. Karger N, Biederer J, Lusse S et al. Quantitation of renal perfusion using arterial spin labeling with FAIR-UFLARE. Magn Reson Imaging 2000; 18: 641–647.
25. Katsurada A, Hagiwara Y, Miyashita K et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293: F956–F960.
26. Kappelgaard AM, Nielsen MD, Giese J. Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 1976; 67: 299–306.
27. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271–274.
28. von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 2015; 32: 343–352.
29. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002; 434: 163–167.
30. Crajoinas RO, Oricchio FT, Pessoa TD et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301: F355–F363.
31. Manotham K, Ongvilawan B, Urusopone P et al. Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study. Intern Med J 2012; 42: e33–e37.
32. Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009; 297: F1647–F1655.
33. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012; 74: 437–444.
34. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010; 38: 1944–1953.
35. Katout M, Zhu H, Rutsky J et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014; 27: 130–139.
36. Bharucha AE, Charkoudian N, Andrews CN et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: R874–R880.
37. Skov J, Persson F, Frokiaer J, Christiansen JS. Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease. Front Endocrinol 2014; 5: 23.
38. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012; 55: 566–578.
39. Kawamura M, Imanishi M, Matsushima Y et al. A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J Pharmacol 1990; 54: 143–149.
40. Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl 2011: 79: S28–S32.